Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Breyanzi“
Suchtreffer
Begriffe & Kennungen
Breyanzi · 4.8 · 19 For patients who received two or more prior lines of therapy for LBCL, Grade 3 or higher cytopenias present
Eintrag öffnenBreyanzi · 4.8 · 20 Reporting of suspected adverse reactions
Eintrag öffnenBreyanzi · 4.8 · Adverse reactions reported are presented below. These reactions are presented by MedDRA system organ class and
Eintrag öffnenBreyanzi · 4.8 · Breyanzi has the potential to induce antibodies against this medicinal product. Humoral immunogenicity of Brey
Eintrag öffnenBreyanzi · 4.8 · Cytokine release syndrome For patients who received one prior line of therapy for LBCL, CRS occurred in 45% of
Eintrag öffnenBreyanzi · 4.8 · Description of selected adverse reactions
Eintrag öffnenBreyanzi · 4.8 · For patients who received Breyanzi for FL, CAR T-cell-associated neurologic toxicities, assessed by the invest
Eintrag öffnenBreyanzi · 4.8 · For patients who received Breyanzi for FL, CRS occurred in 58% of patients, 0.8% of whom experienced Grade 3 C
Eintrag öffnenBreyanzi · 4.8 · For patients who received Breyanzi for FL, Grade 3 or higher cytopenias present at Day 29 following Breyanzi a
Eintrag öffnenBreyanzi · 4.8 · For patients who received Breyanzi for FL, infections (all grades) occurred in 20% of patients. Grade 3 occurr
Eintrag öffnenBreyanzi · 4.8 · For patients who received Breyanzi for MCL, CAR T-cell-associated neurologic toxicities, assessed by the inves
Eintrag öffnenBreyanzi · 4.8 · For patients who received Breyanzi for MCL, Grade 3 or higher cytopenias present at Day 29 following Breyanzi
Eintrag öffnenBreyanzi · 4.8 · For patients who received Breyanzi for MCL, infections (all grades) occurred in 35% of patients. Grade 3 or hi
Eintrag öffnenBreyanzi · 4.8 · For patients who received one prior line of therapy for LBCL, infections (all grades) occurred in 25% of patie
Eintrag öffnenBreyanzi · 4.8 · For patients who received two or more prior lines of therapy for LBCL, CAR T-cell-associated neurologic toxici
Eintrag öffnenBreyanzi · 4.8 · For patients who received two or more prior lines of therapy for LBCL, CRS occurred in 38% of patients, 2% of
Eintrag öffnenBreyanzi · 4.8 · For patients who received two or more prior lines of therapy for LBCL, infections (all grades) occurred in 38%
Eintrag öffnenBreyanzi · 4.8 · Hypogammaglobulinaemia For patients who received one prior line of therapy for LBCL, adverse events of hypogam
Eintrag öffnenBreyanzi · 4.8 · Immunogenicity
Eintrag öffnenBreyanzi · 4.8 · In LBCL clinical studies, 42 of 177 (24%) patients received tocilizumab and/or a corticosteroid for CRS after
Eintrag öffnen